# A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

> **NCT01275066** · PHASE3 · COMPLETED · sponsor: **BioMarin Pharmaceutical** · enrollment: 177 (actual)

## Conditions studied

- MPS IV A

## Interventions

- **DRUG:** BMN 110 Weekly
- **DRUG:** Placebo
- **DRUG:** BMN 110 Every Other Week

## Key facts

- **NCT ID:** NCT01275066
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2014-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01275066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01275066, "A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01275066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*